Comments

Alnylam Pharmaceuticals 분석가 평가

ALNYNASDAQ

Benzinga Data가 제공하는 로고

대중과의 거래

$458.12

-7.22-1.55%

가까이에: Dec 5, 4:00 PM EST

$450.00

-8.12-1.77%

시간외: Dec 5, 5:43 PM EST

개요 뉴스 실적 옵션 가이던스/지침

분석가 평가

내부자 거래 매도 수량 정부 거래 주식 보고서

컨센서스 평점¹

Buy

최고 목표 주가¹

$583.00

최저 목표 주가¹

$220.00

컨센서스 가격 목표¹

$464.48

분석가 평가, 목표 가격, 예측

Alnylam Pharmaceuticals Inc의 컨센서스 목표 주가는 $464.48이며, 30명의 애널리스트 평가를 기반으로 합니다. 최고 목표가는 9월 2, 2025에 Citigroup가 발표한 $583이고, 최저 목표가는 10월 11, 2024에 Cantor Fitzgerald가 발표한 $220입니다. 가장 최근의 애널리스트 평가 3건은 Wells Fargo, Piper Sandler 및 Barclays가 11월 11, 2025, 10월 31, 2025 및 10월 31, 2025에 발표했습니다. Wells Fargo, Piper Sandler 및 Barclays 사이의 평균 목표 주가는 $498.33이며, 이 최신 평가들로부터 Alnylam Pharmaceuticals Inc에 대한 10.74% upside가 시사됩니다.

분석가 추세

8월

9월

10월

11월

매수

보유

매도

강력 매도

분석가 평가

3.6

매수

강력 매수

매수

보유

매도

강력 매도

Alnylam Pharmaceuticals에 대한 애널리스트 평점

					Get Alert
Nov 11, 2025	6.44%	Derek ArchilaWells Fargo 69%	395 479	Previous Equal-Weight Current Equal-Weight	Get Alert
Oct 31, 2025	8.67%	Edward TenthoffPiper Sandler 55%	449 489	Previous Overweight Current Overweight	Get Alert
Oct 31, 2025	17.11%	Gena WangBarclays 57%	460 527	Previous Overweight Current Overweight	Get Alert
Oct 30, 2025	22%	Maury RaycroftJefferies 43%	549 550	Previous Buy Current Buy	Get Alert
Oct 17, 2025	18.89%	Danielle BrillTruist Securities 64%	459 535	Previous Buy Current Buy	Get Alert
Oct 13, 2025	5.11%	Jessica FyeJP Morgan 74%	473 475	Previous Overweight Current Overweight	Get Alert
Oct 10, 2025	26.67%	Patrick R. TrucchioHC Wainwright & Co. 72%	570 570	Previous Buy Current Buy	Get Alert
Oct 6, 2025	5.56%	Michael UlzMorgan Stanley 73%	405 475	Previous Equal-Weight Current Equal-Weight	Get Alert
Oct 6, 2025	10%	Paul MatteisStifel 53%	441 495	Previous Buy Current Buy	Get Alert
Sep 19, 2025	11.11%	Luca IssiRBC Capital 65%	435 500	Previous Outperform Current Outperform	Get Alert
Sep 17, 2025	15.56%	Tazeen AhmadB of A Securities 62%	453 520	Previous Buy Current Buy	Get Alert
Sep 16, 2025	25.78%	Salveen RichterGoldman Sachs 58%	504 566	Previous Buy Current Buy	Get Alert
Sep 15, 2025	22.22%	Maury RaycroftJefferies 43%	453 550	Previous Buy Current Buy	Get Alert
Sep 11, 2025	14.46%	Liisa BaykoEvercore ISI Group 73%	280 515.05	Previous Outperform Current Outperform	Get Alert
Sep 8, 2025	4.44%	Kostas BiliourisBMO Capital 40%	450 470	Previous Outperform Current Outperform	Get Alert
Sep 2, 2025	26.67%	Patrick R. TrucchioHC Wainwright & Co. 72%	570 570	Previous Buy Current Buy	Get Alert
Sep 2, 2025	29.56%	David LebovitzCitigroup 68%	527 583	Previous Buy Current Buy	Get Alert
Aug 7, 2025	26.67%	Patrick TrucchioHC Wainwright & Co. 69%	500 570	Previous Buy Current Buy	Get Alert
Aug 6, 2025	5.56%	Jessica FyeJP Morgan 74%	348 475	Previous Overweight Current Overweight	Get Alert
Aug 4, 2025	8.89%	Leland GershellOppenheimer 75%	490	Previous Perform Current Outperform	Get Alert
Aug 4, 2025	—	Andy ChenWolfe Research 69%	—	Previous Underperform Current Peer Perform	Get Alert
Aug 1, 2025	—	Greg HarrisonScotiabank 74%	342 450	Previous Sector Outperform Current Sector Outperform	Get Alert
Aug 1, 2025	22.22%	Eliana MerleUBS 62%	403 550	Previous Buy Current Buy	Get Alert
Aug 1, 2025	-7.78%	Whitney IjemCanaccord Genuity 71%	390 415	Previous Buy Current Buy	Get Alert
Aug 1, 2025	-12.22%	Tiago FauthWells Fargo 54%	333 395	Previous Equal-Weight Current Equal-Weight	Get Alert
Aug 1, 2025	-5.78%	Martin AusterRaymond James 66%	370 424	Previous Outperform Current Outperform	Get Alert
Aug 1, 2025	2.22%	Gena WangBarclays 57%	329 460	Previous Overweight Current Overweight	Get Alert
Aug 1, 2025	-0.22%	Edward TenthoffPiper Sandler 55%	304 449	Previous Overweight Current Overweight	Get Alert
Aug 1, 2025	-11.11%	Keay NakaeChardan Capital 74%	325 400	Previous Buy Current Buy	Get Alert
Aug 1, 2025	-10%	Michael UlzMorgan Stanley 73%	312 405	Previous Equal-Weight Current Equal-Weight	Get Alert
Jul 31, 2025	6.22%	Joseph StringerNeedham 78%	377 478	Previous Buy Current Buy	Get Alert
Jul 29, 2025	-17.78%	Martin AusterRaymond James 66%	308 370	Previous Outperform Current Outperform	Get Alert
Jul 21, 2025	-14.44%	Danielle BrillTruist Securities 64%	385	Previous Initiates Current Buy	Get Alert
Jul 16, 2025	-22.67%	Jessica FyeJP Morgan 74%	338 348	Previous Overweight Current Overweight	Get Alert
Jul 11, 2025	-10.22%	David LebovitzCitigroup 68%	364 404	Previous Buy Current Buy	Get Alert
Jul 11, 2025	-20.22%	Tazeen AhmadB of A Securities 62%	336 359	Previous Buy Current Buy	Get Alert
Jul 7, 2025	-14.67%	Maury RaycroftJefferies 43%	328 384	Previous Buy Current Buy	Get Alert
Jun 30, 2025	-26%	Tiago FauthWells Fargo 54%	287 333	Previous Equal-Weight Current Equal-Weight	Get Alert
Jun 26, 2025	-16.22%	Joseph StringerNeedham 78%	320 377	Previous Buy Current Buy	Get Alert
Jun 24, 2025	-20%	Kostas BiliourisBMO Capital 40%	300 360	Previous Outperform Current Outperform	Get Alert
Jun 12, 2025	-24.89%	Jessica FyeJP Morgan 74%	330 338	Previous Overweight Current Overweight	Get Alert
May 2, 2025	-22.44%	Eliana MerleUBS 62%	331 349	Previous Buy Current Buy	Get Alert
May 2, 2025	-27.78%	Keay NakaeChardan Capital 74%	300 325	Previous Buy Current Buy	Get Alert
Apr 11, 2025	-40.44%	Michael UlzMorgan Stanley 73%	268 284	Previous Equal-Weight Current Equal-Weight	Get Alert
Apr 9, 2025	-28.89%	Joseph StringerNeedham 78%	320 320	Previous Buy Current Buy	Get Alert
Apr 2, 2025	11.11%	Patrick TrucchioHC Wainwright & Co. 69%	500 500	Previous Buy Current Buy	Get Alert
Mar 31, 2025	-24%	Greg HarrisonScotiabank 74%	338 342	Previous Sector Outperform Current Sector Outperform	Get Alert
Mar 31, 2025	-21.56%	Joshua Smith Redburn Atlantic 75%	353	Previous Initiates Current Buy	Get Alert
Mar 31, 2025	-23.33%	Paul MatteisStifel 53%	300 345	Previous Buy Current Buy	Get Alert
Mar 24, 2025	-27.11%	Jessica FyeJP Morgan 74%	280 328	Previous Neutral Current Overweight	Get Alert
Mar 21, 2025	-22%	David LebovitzCitigroup 68%	338 351	Previous Buy Current Buy	Get Alert
Mar 21, 2025	-13.33%	Whitney IjemCanaccord Genuity 71%	385 390	Previous Buy Current Buy	Get Alert
Mar 21, 2025	-26.67%	Luca IssiRBC Capital 65%	310 330	Previous Outperform Current Outperform	Get Alert
Mar 21, 2025	-24.89%	Greg HarrisonScotiabank 74%	300 338	Previous Sector Outperform Current Sector Outperform	Get Alert
Mar 21, 2025	-36.22%	Tiago FauthWells Fargo 54%	275 287	Previous Equal-Weight Current Equal-Weight	Get Alert
Mar 21, 2025	-27.78%	Tazeen AhmadB of A Securities 62%	302 325	Previous Buy Current Buy	Get Alert
Mar 21, 2025	-33.33%	Keay NakaeChardan Capital 74%	300 300	Previous Buy Current Buy	Get Alert
Mar 21, 2025	-28.89%	Joseph StringerNeedham 78%	320 320	Previous Buy Current Buy	Get Alert
Mar 11, 2025	-37.78%	Jessica FyeJP Morgan 74%	272 280	Previous Neutral Current Neutral	Get Alert
Feb 26, 2025	-31.11%	Luca IssiRBC Capital 65%	310 310	Previous Outperform Current Outperform	Get Alert
Feb 26, 2025	-33.33%	Keay NakaeChardan Capital 74%	300 300	Previous Buy Current Buy	Get Alert
Feb 26, 2025	-28.89%	Joseph StringerNeedham 78%	320 320	Previous Buy Current Buy	Get Alert
Feb 25, 2025	11.11%	Patrick TrucchioHC Wainwright & Co. 69%	400 500	Previous Buy Current Buy	Get Alert
Feb 24, 2025	11.11%	Patrick TrucchioHC Wainwright & Co. 69%	400 500	Previous Buy Current Buy	Get Alert
Feb 18, 2025	-14.44%	Whitney IjemCanaccord Genuity 71%	384 385	Previous Buy Current Buy	Get Alert
Feb 14, 2025	-33.33%	Greg HarrisonScotiabank 74%	300 310	Previous Sector Outperform Current Sector Outperform	Get Alert
Feb 14, 2025	-36.89%	Michael UlzMorgan Stanley 73%	275 284	Previous Equal-Weight Current Equal-Weight	Get Alert
Feb 14, 2025	-28.89%	Joseph StringerNeedham 78%	320 320	Previous Buy Current Buy	Get Alert
Feb 11, 2025	-33.33%	Luca IssiRBC Capital 65%	300 300	Previous Outperform Current Outperform	Get Alert
Jan 21, 2025	-33.33%	Luca IssiRBC Capital 65%	300 300	Previous Outperform Current Outperform	Get Alert
Jan 13, 2025	-11.11%	Patrick TrucchioHC Wainwright & Co. 69%	400 400	Previous Buy Current Buy	Get Alert
Jan 13, 2025	-28.89%	Joseph StringerNeedham 78%	320 320	Previous Buy Current Buy	Get Alert
Jan 7, 2025	-31.11%	William PickeringBernstein 47%	310 314	Previous Outperform Current Outperform	Get Alert
Nov 18, 2024	-34.22%	Edward TenthoffPiper Sandler 55%	296 296	Previous Overweight Current Overweight	Get Alert
Nov 18, 2024	-11.11%	Patrick TrucchioHC Wainwright & Co. 69%	400 400	Previous Buy Current Buy	Get Alert
Nov 12, 2024	—	Andy ChenWolfe Research 69%	—	Previous Peer Perform Current Underperform	Get Alert
Nov 4, 2024	-11.11%	Patrick TrucchioHC Wainwright & Co. 69%	400 400	Previous Buy Current Buy	Get Alert
Nov 1, 2024	-33.78%	Gary NachmanRaymond James 62%	275 298	Previous Outperform Current Outperform	Get Alert
Nov 1, 2024	-33.33%	Luca IssiRBC Capital 65%	300 300	Previous Outperform Current Outperform	Get Alert
Nov 1, 2024	-31.11%	Greg HarrisonScotiabank 74%	305 310	Previous Sector Outperform Current Sector Outperform	Get Alert
Nov 1, 2024	-26.89%	Gena WangBarclays 57%	295 329	Previous Overweight Current Overweight	Get Alert
Nov 1, 2024	-14.67%	Whitney IjemCanaccord Genuity 71%	366 384	Previous Buy Current Buy	Get Alert
Nov 1, 2024	-33.33%	Keay NakaeChardan Capital 74%	300 300	Previous Buy Current Buy	Get Alert
Nov 1, 2024	-28.89%	Joseph StringerNeedham 78%	320 320	Previous Buy Current Buy	Get Alert
Oct 21, 2024	-17.56%	Ritu BaralTD Cowen 59%	282 371	Previous Buy Current Buy	Get Alert
Oct 18, 2024	-11.11%	Patrick TrucchioHC Wainwright & Co. 69%	400 400	Previous Buy Current Buy	Get Alert
Oct 16, 2024	-32.22%	Greg HarrisonScotiabank 74%	305	Previous Initiates Current Sector Outperform	Get Alert
Oct 14, 2024	-30.22%	Tazeen AhmadB of A Securities 62%	307 314	Previous Buy Current Buy	Get Alert
Oct 11, 2024	-33.33%	Keay NakaeChardan Capital 74%	300 300	Previous Buy Current Buy	Get Alert
Oct 11, 2024	-51.11%	Olivia BrayerCantor Fitzgerald 57%	220 220	Previous Neutral Current Neutral	Get Alert
Oct 10, 2024	-33.33%	Luca IssiRBC Capital 65%	300 300	Previous Outperform Current Outperform	Get Alert
Oct 10, 2024	-28.89%	Joseph StringerNeedham 78%	320 320	Previous Buy Current Buy	Get Alert
Sep 19, 2024	-33.33%	Luca IssiRBC Capital 65%	300 300	Previous Outperform Current Outperform	Get Alert
Sep 9, 2024	-51.11%	Olivia BrayerCantor Fitzgerald 57%	220 220	Previous Neutral Current Neutral	Get Alert
Sep 4, 2024	-33.33%	Luca IssiRBC Capital 65%	300 300	Previous Outperform Current Outperform	Get Alert
Sep 4, 2024	-31.78%	Tazeen AhmadB of A Securities 62%	295 307	Previous Buy Current Buy	Get Alert
Aug 30, 2024	-11.11%	Patrick TrucchioHC Wainwright & Co. 69%	400 400	Previous Buy Current Buy	Get Alert
Aug 26, 2024	-37.78%	Jessica FyeJP Morgan 74%	248 280	Previous Neutral Current Neutral	Get Alert
Aug 20, 2024	-11.11%	Patrick TrucchioHC Wainwright & Co. 69%	400 400	Previous Buy Current Buy	Get Alert
Aug 16, 2024	-17.78%	Salveen RichterGoldman Sachs 58%	198 370	Previous Neutral Current Buy	Get Alert

FAQ

Alnylam Pharmaceuticals (ALNY) 주식의 목표 가격은 얼마입니까?

Alnylam Pharmaceuticals (NASDAQ:ALNY)의 최신 목표 주가는 11월 11, 2025에 Wells Fargo에 의해 보고되었습니다. 이 애널리스트 기관은 $479.00에 대한 가격 목표를 설정했으며, 12개월 이내에 ALNY이(가) rise될 것으로 예상합니다 (가능한 6.44% upside). 지난 1년간 73개의 애널리스트 기관이 평가를 보고했습니다.

Alnylam Pharmaceuticals (ALNY)에 대한 가장 최근의 애널리스트 평가는 무엇인가요?

Alnylam Pharmaceuticals (NASDAQ:ALNY)에 대한 최신 애널리스트 평가는 Wells Fargo에 의해 제공되었으며, Alnylam Pharmaceuticals은(는) equal-weight 평가를 유지했다합니다.

Alnylam Pharmaceuticals (ALNY)에 대한 마지막 업그레이드는 언제 있었나요?

Alnylam Pharmaceuticals Inc에 대한 마지막 업그레이드는 8월 4, 2025에 발생했습니다. 이 때 Oppenheimer는 $490로 가격 목표를 올렸습니다. Oppenheimer는 이전에 Alnylam Pharmaceuticals Inc에 대해 a perform를 가지고 있었습니다.

Alnylam Pharmaceuticals (ALNY)에 대한 마지막 다운그레이드는 언제 있었나요?

Alnylam Pharmaceuticals Inc에 대한 마지막 다운그레이드는 11월 12, 2024에 발생했습니다. 이 때 Wolfe Research가 Alnylam Pharmaceuticals Inc에 대해 가격 목표를 N/A에서 N/A로 변경했습니다.

Alnylam Pharmaceuticals (ALNY)에 대한 다음 애널리스트 평가는 언제 게시 또는 업데이트될 예정인가요?

애널리스트들은 주식 평가를 내리기 위해 철저한 연구를 진행합니다. 이 연구에는 공개된 재무 보고서를 검토하고, Alnylam Pharmaceuticals의 경영진 및 고객과 대화하며, 실적 회의 통화를 듣는 것이 포함됩니다. 대부분의 애널리스트들은 이를 매 분기마다 수행하므로, 한 해에는 회사당 애널리스트 당 4번의 평가를 받을 수 있습니다. Alnylam Pharmaceuticals에 대한 마지막 평가는 11월 11, 2025에 제출되었으므로, 다음 평가가 11월 11, 2026쯤에 제공될 것으로 예상됩니다.

애널리스트 평가 Alnylam Pharmaceuticals (ALNY)가 올바른가요?

평가는 주관적이며 변할 수 있지만, 최신 Alnylam Pharmaceuticals (ALNY) 평가는 유지했다로, 가격 목표는 $395.00에서 $479.00으로 조정되었습니다. 현재 Alnylam Pharmaceuticals (ALNY)의 가격은 $450.00로, 이는 애널리스트의 예측 범위에서 within입니다.

검색 애널리스트 평가 및 가격 목표 모든 주식에 대한